Annual FCF
-$22.59 M
+$12.10 M+34.88%
31 December 2023
Summary:
Cytosorbents annual free cash flow is currently -$22.59 million, with the most recent change of +$12.10 million (+34.88%) on 31 December 2023. During the last 3 years, it has fallen by -$15.30 million (-209.92%). CTSO annual FCF is now -846.28% below its all-time high of -$2.39 million, reached on 31 December 2008.CTSO Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$2.76 M
+$2.15 M+43.85%
30 September 2024
Summary:
Cytosorbents quarterly free cash flow is currently -$2.76 million, with the most recent change of +$2.15 million (+43.85%) on 30 September 2024. Over the past year, it has increased by +$2.70 million (+49.49%). CTSO quarterly FCF is now -291.53% below its all-time high of $1.44 million, reached on 30 June 2020.CTSO Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$19.17 M
+$2.70 M+12.36%
30 September 2024
Summary:
Cytosorbents TTM free cash flow is currently -$19.17 million, with the most recent change of +$2.70 million (+12.36%) on 30 September 2024. Over the past year, it has increased by +$2.42 million (+11.21%). CTSO TTM FCF is now -158364.46% below its all-time high of -$12.10 thousand, reached on 30 November 2005.CTSO TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CTSO Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.9% | +49.5% | +11.2% |
| 3 y3 years | -209.9% | +46.4% | -54.0% |
| 5 y5 years | -82.8% | +50.0% | -14.3% |
CTSO Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -209.9% | +34.9% | at high | +78.3% | -54.0% | +47.2% |
| 5 y | 5 years | -209.9% | +34.9% | -291.5% | +78.3% | -194.0% | +47.2% |
| alltime | all time | -846.3% | +34.9% | -291.5% | +78.3% | <-9999.0% | +47.2% |
Cytosorbents Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$2.76 M(-43.8%) | -$19.17 M(-12.4%) |
| June 2024 | - | -$4.91 M(-0.9%) | -$21.88 M(-7.9%) |
| Mar 2024 | - | -$4.96 M(-24.2%) | -$23.76 M(+5.2%) |
| Dec 2023 | -$22.59 M(-34.9%) | -$6.54 M(+19.8%) | -$22.59 M(+4.6%) |
| Sept 2023 | - | -$5.46 M(-19.6%) | -$21.59 M(-8.4%) |
| June 2023 | - | -$6.79 M(+79.2%) | -$23.58 M(-20.1%) |
| Mar 2023 | - | -$3.79 M(-31.6%) | -$29.51 M(-14.9%) |
| Dec 2022 | -$34.69 M(+89.7%) | -$5.55 M(-25.6%) | -$34.69 M(-4.5%) |
| Sept 2022 | - | -$7.45 M(-41.4%) | -$36.31 M(+6.8%) |
| June 2022 | - | -$12.72 M(+41.9%) | -$34.01 M(+39.9%) |
| Mar 2022 | - | -$8.97 M(+25.2%) | -$24.30 M(+32.9%) |
| Dec 2021 | -$18.29 M(+150.9%) | -$7.16 M(+39.1%) | -$18.29 M(+46.9%) |
| Sept 2021 | - | -$5.15 M(+70.5%) | -$12.45 M(+13.3%) |
| June 2021 | - | -$3.02 M(+2.4%) | -$10.98 M(+68.4%) |
| Mar 2021 | - | -$2.95 M(+122.9%) | -$6.52 M(-10.5%) |
| Dec 2020 | -$7.29 M(-60.1%) | -$1.32 M(-64.1%) | -$7.29 M(-30.5%) |
| Sept 2020 | - | -$3.69 M(-356.0%) | -$10.49 M(-14.9%) |
| June 2020 | - | $1.44 M(-138.8%) | -$12.33 M(-28.7%) |
| Mar 2020 | - | -$3.72 M(-17.9%) | -$17.28 M(-5.4%) |
| Dec 2019 | -$18.28 M(+47.9%) | -$4.53 M(-18.0%) | -$18.28 M(+8.9%) |
| Sept 2019 | - | -$5.52 M(+57.1%) | -$16.78 M(+18.4%) |
| June 2019 | - | -$3.52 M(-25.4%) | -$14.17 M(-1.6%) |
| Mar 2019 | - | -$4.71 M(+55.5%) | -$14.40 M(+16.5%) |
| Dec 2018 | -$12.36 M(+51.9%) | -$3.03 M(+4.1%) | -$12.36 M(+19.8%) |
| Sept 2018 | - | -$2.91 M(-22.2%) | -$10.32 M(+1.9%) |
| June 2018 | - | -$3.74 M(+39.8%) | -$10.13 M(+17.5%) |
| Mar 2018 | - | -$2.68 M(+169.9%) | -$8.63 M(+6.0%) |
| Dec 2017 | -$8.14 M(+11.1%) | -$991.50 K(-63.6%) | -$8.14 M(-2.2%) |
| Sept 2017 | - | -$2.72 M(+21.8%) | -$8.32 M(+0.8%) |
| June 2017 | - | -$2.24 M(+2.2%) | -$8.26 M(+1.3%) |
| Mar 2017 | - | -$2.19 M(+85.9%) | -$8.15 M(+11.2%) |
| Dec 2016 | -$7.33 M(-24.4%) | -$1.18 M(-55.7%) | -$7.33 M(-14.7%) |
| Sept 2016 | - | -$2.65 M(+24.9%) | -$8.59 M(+2.4%) |
| June 2016 | - | -$2.13 M(+55.4%) | -$8.39 M(-6.4%) |
| Mar 2016 | - | -$1.37 M(-44.0%) | -$8.96 M(-7.6%) |
| Dec 2015 | -$9.69 M | -$2.44 M(-0.2%) | -$9.69 M(+1.7%) |
| Sept 2015 | - | -$2.45 M(-9.2%) | -$9.53 M(+5.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | -$2.70 M(+28.4%) | -$9.07 M(+14.5%) |
| Mar 2015 | - | -$2.10 M(-7.9%) | -$7.92 M(+19.2%) |
| Dec 2014 | -$6.65 M(+79.4%) | -$2.28 M(+14.5%) | -$6.65 M(+18.0%) |
| Sept 2014 | - | -$1.99 M(+28.3%) | -$5.63 M(+33.7%) |
| June 2014 | - | -$1.55 M(+87.8%) | -$4.21 M(+13.3%) |
| Mar 2014 | - | -$826.00 K(-34.8%) | -$3.72 M(+0.4%) |
| Dec 2013 | -$3.71 M(+1.4%) | -$1.27 M(+122.1%) | -$3.71 M(+15.1%) |
| Sept 2013 | - | -$570.40 K(-46.0%) | -$3.22 M(-1.8%) |
| June 2013 | - | -$1.06 M(+30.2%) | -$3.28 M(-3.1%) |
| Mar 2013 | - | -$811.60 K(+4.1%) | -$3.38 M(-7.4%) |
| Dec 2012 | -$3.66 M(-5.8%) | -$779.70 K(+23.6%) | -$3.66 M(-8.3%) |
| Sept 2012 | - | -$630.70 K(-45.7%) | -$3.98 M(-11.0%) |
| June 2012 | - | -$1.16 M(+7.2%) | -$4.48 M(+2.3%) |
| Mar 2012 | - | -$1.08 M(-2.3%) | -$4.38 M(+12.8%) |
| Dec 2011 | -$3.88 M(+46.9%) | -$1.11 M(-1.2%) | -$3.88 M(+8.3%) |
| Sept 2011 | - | -$1.12 M(+5.8%) | -$3.58 M(+15.5%) |
| June 2011 | - | -$1.06 M(+80.4%) | -$3.10 M(+10.4%) |
| Mar 2011 | - | -$588.00 K(-27.5%) | -$2.81 M(+6.3%) |
| Dec 2010 | -$2.64 M(-1.7%) | -$810.60 K(+26.3%) | -$2.64 M(+15.1%) |
| Sept 2010 | - | -$642.00 K(-16.4%) | -$2.30 M(-2.5%) |
| June 2010 | - | -$768.30 K(+82.1%) | -$2.35 M(+1.6%) |
| Mar 2010 | - | -$421.80 K(-9.0%) | -$2.32 M(-13.8%) |
| Dec 2009 | -$2.69 M(+12.6%) | -$463.40 K(-33.8%) | -$2.69 M(+1.2%) |
| Sept 2009 | - | -$700.30 K(-4.2%) | -$2.66 M(-11.9%) |
| June 2009 | - | -$731.20 K(-7.9%) | -$3.02 M(+3.4%) |
| Mar 2009 | - | -$794.00 K(+84.1%) | -$2.92 M(+22.2%) |
| Dec 2008 | -$2.39 M(-10.3%) | -$431.20 K(-59.3%) | -$2.39 M(-5.2%) |
| Sept 2008 | - | -$1.06 M(+67.4%) | -$2.52 M(+16.4%) |
| June 2008 | - | -$632.60 K(+138.9%) | -$2.16 M(-3.5%) |
| Mar 2008 | - | -$264.80 K(-53.0%) | -$2.24 M(-15.7%) |
| Dec 2007 | -$2.66 M(-8.7%) | -$563.00 K(-20.0%) | -$2.66 M(+26.8%) |
| Sept 2007 | - | -$703.50 K(-1.1%) | -$2.10 M(+50.4%) |
| June 2007 | - | -$711.50 K(+4.1%) | -$1.40 M(+104.1%) |
| Mar 2007 | - | -$683.50 K(>+9900.0%) | -$683.50 K(+4225.9%) |
| Dec 2006 | -$2.91 M | - | - |
| Feb 2006 | - | -$3700.00(-100.8%) | -$15.80 K(+30.6%) |
| Nov 2005 | - | $464.50 K(-197.5%) | -$12.10 K(-97.5%) |
| Aug 2005 | - | -$476.60 K | -$476.60 K |
FAQ
- What is Cytosorbents annual free cash flow?
- What is the all time high annual FCF for Cytosorbents?
- What is Cytosorbents annual FCF year-on-year change?
- What is Cytosorbents quarterly free cash flow?
- What is the all time high quarterly FCF for Cytosorbents?
- What is Cytosorbents quarterly FCF year-on-year change?
- What is Cytosorbents TTM free cash flow?
- What is the all time high TTM FCF for Cytosorbents?
- What is Cytosorbents TTM FCF year-on-year change?
What is Cytosorbents annual free cash flow?
The current annual FCF of CTSO is -$22.59 M
What is the all time high annual FCF for Cytosorbents?
Cytosorbents all-time high annual free cash flow is -$2.39 M
What is Cytosorbents annual FCF year-on-year change?
Over the past year, CTSO annual free cash flow has changed by +$12.10 M (+34.88%)
What is Cytosorbents quarterly free cash flow?
The current quarterly FCF of CTSO is -$2.76 M
What is the all time high quarterly FCF for Cytosorbents?
Cytosorbents all-time high quarterly free cash flow is $1.44 M
What is Cytosorbents quarterly FCF year-on-year change?
Over the past year, CTSO quarterly free cash flow has changed by +$2.70 M (+49.49%)
What is Cytosorbents TTM free cash flow?
The current TTM FCF of CTSO is -$19.17 M
What is the all time high TTM FCF for Cytosorbents?
Cytosorbents all-time high TTM free cash flow is -$12.10 K
What is Cytosorbents TTM FCF year-on-year change?
Over the past year, CTSO TTM free cash flow has changed by +$2.42 M (+11.21%)